With 17 peer-reviewed publications (published or accepted) and over 60 abstracts and presentations, Signatera bespoke molecular residual disease (MRD) assay has been leading the charge of circulating tumor DNA (ctDNA) research.
Learn about the latest advances in ctDNA for all tumor types. Find out how Signatera has been applied in early-stage and late-stage disease. Discover improvements to clinical trial design with Signatera including: identifying early relapsers, enriching for patients potentially most likely to respond to therapy, accelerating time to trial readout, predicting clinical outcomes as early as 6 weeks into treatment.
Dr. Angel Augusto Rodriguez is a board-certified medical oncologist who specializes in breast medical oncology and conducted clinical research with circulating tumor DNA. Before joining Natera, Dr. Rodriguez practiced at Austin Cancer Centers and Houston Methodist Cancer Center where he was Director of the Clinical Trials Office and the Triple Negative Breast Cancer Clinic. While at Houston Methodist he was principal investigator of clinical trials and conducted clinical research with circulating tumor DNA.
Dr. Simmons leads oncology biopharma partnerships at Natera. He received his Bachelor of Science degree in Biology at American University, graduating with Honors. Dr Simmons earned his PhD in Tumor Biology from Georgetown University. Before joining Natera, he completed his postdoctoral fellowship at the National Cancer Institute (NCI) and served as Vice President of Translational Medicine at Personal Genome Diagnostics (PGDx).
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.